Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis

Table 1

Comparison of clinical parameters among cirrhotic patients according to VWF multimer patterns.

Variables	VWF multimer pattrens			a versus b	a versus c	b versus c
	Degraded^a (𝑛=15)	Normal^b (𝑛=26)	Unusuallylarge^c (𝑛=8)
ADAMTS13 : AC (%) (ELISA)	47±24	44±13	26±14	n.s.	𝑃<.05	𝑃<.01
VWF : RCo (%)	110±92	196±134	216±110	𝑃<.05	𝑃<.05	n.s.
Child-Pugh score	8.6±2.5	10.9±2.1	12.4±1.7	𝑃<.01	𝑃<.005	n.s.
Serum albumin (g/dL)	3.07±0.54	2.85±0.54	2.59±0.25	n.s.	𝑃<.05	n.s.
Cholinesterase (IU/L)	126±62	78±64	60±36	𝑃<.05	𝑃<.02	n.s.
Total cholesterol (mg/dL)	142±51	93±45	88±40	𝑃<.01	𝑃<.03	n.s.
Hemoglobin (g/dL)	11.0±1.7	9.3±2.0	8.9±1.7	𝑃<.02	𝑃<.02	n.s.
Serum creatinine (mg/dL)	1.06±0.72	1.11±0.79	2.43±2.16	n.s.	𝑃<.05	𝑃<.03
Blood urea nitrogen (mg/dL)	22±17	30±21	74±62	n.s.	𝑃<.01	𝑃<.01
Blood ammonia (μg/dL)	87±50	100±39	144±53	n.s.	𝑃<.05	𝑃<.05

VWF: von Willebrand factor; ADAMTS13 : AC : ADAMTS13 activity; ELISA : enzyme-linked immunosorbent assay; VWF : RCo: VWF ristocetin cofactor activity; n.s.: not significant. (Partially modified from Uemura et al., [30]).